Subdissociative intranasal ketamine plus standard pain therapy versus standard pain therapy in the treatment of paediatric sickle cell disease vaso-occlusive crises in resource-limited settings: study protocol for a randomised controlled trial

James R Young, Hendry Robert Sawe, Juma A Mfinanga, Ernest Nshom, Ethan Helm, Charity G Moore, Michael S Runyon, Stacy L Reynolds, James R Young, Hendry Robert Sawe, Juma A Mfinanga, Ernest Nshom, Ethan Helm, Charity G Moore, Michael S Runyon, Stacy L Reynolds

Abstract

Introduction: Pediatric sickle cell disease, highly prevalent in sub-Saharan Africa, carries great morbidity and mortality risk. Limited resources and monitoring make management of acute vaso-occlusive crises challenging. This study aims to evaluate the efficacy and safety of subdissociative intranasal ketamine as a cheap, readily available and easily administered adjunct to standard pain therapy. We hypothesise that subdissociative, intranasal ketamine may significantly augment current approaches to pain management in resource-limited settings in a safe and cost-effective manner.

Methods and analysis: This is a multicentred, randomised, double-blind, placebo-controlled trial enrolling children 4-16 years of age with sickle cell disease and painful vaso-occlusive pain crises. Study sites include two sub-Saharan teaching and referral hospitals with acute intake areas. All patients receive standard analgesic therapy during evaluation. Patients randomised to the treatment arm receive 1 mg/kg intranasal ketamine at onset of therapy, while placebo arm participants receive volume-matched intranasal normal saline. All participants and clinical staff are blinded to the treatment allocation. Data will be analysed on an intention-to-treat basis. Primary endpoints are changes in self-report pain scales (Faces Pain Scale-Revised) at 30, 60 and 120 minutes and rates of adverse events. Secondary endpoints include hospital length of stay, total analgesia use and quality of life assessment 2-3 weeks postintervention.

Ethics and dissemination: The research methods for this study have been approved by the Cameroon Baptist Convention Health Board Institutional Review Board (IRB2015-07), the Tanzanian National Institute for Medical Research (NIMR/HQ/R.8a/Vol. IX/2299), Muhimbili National Hospital IRB (MNH/IRB/I/2015/14) and the Tanzanian Food and Drugs Authority (TFDA0015/CTR/0015/9). Data reports will be provided to the Data and Safety Monitoring Board (DSMB) periodically throughout the study as well as all reports of adverse events. All protocol amendments will also be reviewed by the DSMB. Study results, regardless of direction or amplitude, will be submitted for publication in relevant peer-reviewed journals.

Trial registration: ClinicalTrials.Gov, NCT02573714. Date of registration: 8 October 2015. Pre-results.

Keywords: Intranasal; Ketamine; Opioids; Pain; Vasoocclusive crisis; sickle cell disease.

Conflict of interest statement

Competing interests: No authors disclosed a relevant conflict of interest.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Figures

Figure 1
Figure 1
Study flow diagram.

References

    1. Alli NA, Patel M, Alli HD, et al. . Recommendations for the management of sickle cell disease in South Africa. S Afr Med J 2014;104:743–51.10.7196/SAMJ.8470
    1. World Health Organization. Sickle-cell anaemia: report by the secretariat 59th World Health Assembly. 11, 2006. .
    1. Diallo D, Tchernia G. Sickle cell disease in Africa. Curr Opin Hematol 2002;9:111–6.10.1097/00062752-200203000-00005
    1. Platt OS, Thorington BD, Brambilla DJ, et al. . Pain in sickle cell disease. rates and risk factors. N Engl J Med 1991;325:11–16.10.1056/NEJM199107043250103
    1. Gill FM, Sleeper LA, Weiner SJ, et al. . Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood 1995;86:776–83.
    1. Olabode JO, Shokunbi WA. Types of crises in sickle cell disease patients presenting at the haematology day care unit (HDCU), University College Hospital (UCH), Ibadan. West Afr J Med 2006;25:284–8.
    1. Quinn CT, Shull EP, Ahmad N, et al. . Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia. Blood 2007;109:40–5.10.1182/blood-2006-02-005082
    1. Ambe JP, Mava Y, Chama R, et al. . Clinical features of sickle cell anaemia in northern nigerian children. West Afr J Med 2012;31:81–5.
    1. Piel FB, Hay SI, Gupta S, et al. . Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. PLoS Med 2013;10:e1001484.10.1371/journal.pmed.1001484
    1. Grosse SD, Odame I, Atrash HK, et al. . Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med 2011;41(6 Suppl 4):S398–405.10.1016/j.amepre.2011.09.013
    1. Ogun GO, Ebili H, Kotila TR. Autopsy findings and pattern of mortality in Nigerian sickle cell disease patients. Pan Afr Med J 2014;18:30.10.11604/pamj.2014.18.30.4043
    1. Aloni MN, Nkee L. Challenge of managing sickle cell disease in a pediatric population living in kinshasa, democratic republic of congo: a sickle cell center experience. Hemoglobin 2014;38:196–200.10.3109/03630269.2014.896810
    1. Makani J, Ofori-Acquah SF, Nnodu O, et al. . Sickle cell disease: new opportunities and challenges in Africa. ScientificWorldJournal 2013;2013:1–16.10.1155/2013/193252
    1. World Health Organisation. WHO Model List of Essential Medicines for Children, 5 th List (April 2015) WHO Medicines website. (accessed 8 Feb 2016).
    1. Donnelly RF. Stability of diluted ketamine packaged in glass vials. Can J Hosp Pharm 2013;66:198.10.4212/cjhp.v66i3.1259
    1. Walker SE LS, DeAngelis C. Stability and compatability of hydromorphone and ketamine in normal saline. CJHP 2001:193–201.
    1. Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg 1998;87:1186–93.
    1. Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth 1989;36:186–97.10.1007/BF03011442
    1. Smith DC, Mader TJ, Smithline HA. Low dose intravenous ketamine as an analgesic: a pilot study using an experimental model of acute pain. Am J Emerg Med 2001;19:531–2.10.1053/ajem.2001.27152
    1. Green SM, Roback MG, Krauss B, et al. . Predictors of airway and respiratory adverse events with ketamine sedation in the emergency department: an individual-patient data meta-analysis of 8,282 children. Ann Emerg Med 2009;54:158–68.10.1016/j.annemergmed.2008.12.011
    1. Green SM, Clem KJ, Rothrock SG. Ketamine safety profile in the developing world: survey of practitioners. Acad Emerg Med 1996;3:598–604.
    1. White JM, Ryan CF. Pharmacological properties of ketamine. Drug Alcohol Rev 1996;15:145–55.10.1080/09595239600185801
    1. Jennings PA, Cameron P, Bernard S. Ketamine as an analgesic in the pre-hospital setting: a systematic review. Acta Anaesthesiol Scand 2011;55:638–43.10.1111/j.1399-6576.2011.02446.x
    1. Yeaman F, Oakley E, Meek R, et al. . Sub-dissociative dose intranasal ketamine for limb injury pain in children in the emergency department: a pilot study. Emerg Med Australas 2013;25:161–7.10.1111/1742-6723.12059
    1. Johansson J, Sjöberg J, Nordgren M, et al. . Prehospital analgesia using nasal administration of S-ketamine--a case series. Scand J Trauma Resusc Emerg Med 2013;21:38.10.1186/1757-7241-21-38
    1. Andolfatto G, Willman E, Joo D, et al. . Intranasal ketamine for analgesia in the emergency department: a prospective observational series. Acad Emerg Med 2013;20:1050–4.10.1111/acem.12229
    1. Bredmose PP, Grier G, Davies GE, et al. . Pre-hospital use of ketamine in paediatric trauma. Acta Anaesthesiol Scand 2009;53:543–5.10.1111/j.1399-6576.2008.01852.x
    1. Bredlau AL, Thakur R, Korones DN, et al. . Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature. Pain Med 2013;14:1505–17.10.1111/pme.12182
    1. Sheehy KA, Muller EA, Lippold C, et al. . Subanesthetic ketamine infusions for the treatment of children and adolescents with chronic pain: a longitudinal study. BMC Pediatr 2015;15:198.10.1186/s12887-015-0515-4
    1. Fisher AD, Rippee B, Shehan H, et al. . Prehospital analgesia with ketamine for combat wounds: a case series. J Spec Oper Med 2014;14:11–17.
    1. Petz LN, Tyner S, Barnard E, et al. . Prehospital and en route analgesic use in the combat setting: a prospectively designed, multicenter, observational study. Mil Med 2015;180 (3 Suppl):14–18.10.7205/MILMED-D-14-00383
    1. Zempsky WT, Loiselle KA, Corsi JM, et al. . Use of low-dose ketamine infusion for pediatric patients with sickle cell disease-related pain: a case series. Clin J Pain 2010;26:163–7.10.1097/AJP.0b013e3181b511ab
    1. Fu ES, Miguel R, Scharf JE. Preemptive ketamine decreases postoperative narcotic requirements in patients undergoing abdominal surgery. Anesth Analg 1997;84:1086–90.
    1. Nesher N, Ekstein MP, Paz Y, et al. . Morphine with adjuvant ketamine vs higher dose of morphine alone for immediate postthoracotomy analgesia. Chest 2009;136:245–52.10.1378/chest.08-0246
    1. Tawfic QA, Faris AS, Kausalya R. The role of a low-dose ketamine-midazolam regimen in the management of severe painful crisis in patients with sickle cell disease. J Pain Symptom Manage 2014;47:334–40.10.1016/j.jpainsymman.2013.03.012
    1. Uprety D, Baber A, Foy M. Ketamine infusion for sickle cell pain crisis refractory to opioids: a case report and review of literature. Ann Hematol 2014;93:769–71.10.1007/s00277-013-1954-3
    1. Laulin JP, Maurette P, Corcuff JB, et al. . The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance. Anesth Analg 2002;94:1263–9.10.1097/00000539-200205000-00040
    1. Stubhaug A, Breivik H, Eide PK, et al. . Mapping of punctuate hyperalgesia around a surgical incision demonstrates that ketamine is a powerful suppressor of central sensitization to pain following surgery. Acta Anaesthesiol Scand 1997;41:1124–32.10.1111/j.1399-6576.1997.tb04854.x
    1. Subramaniam K, Subramaniam B, Steinbrook RA. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesth Analg 2004;99:482–95.10.1213/01.ANE.0000118109.12855.07
    1. Vadivelu N, Schermer E, Kodumudi V, et al. . Role of ketamine for analgesia in adults and children. J Anaesthesiol Clin Pharmacol 2016;32:298.10.4103/0970-9185.168149
    1. Graudins A, Meek R, Egerton-Warburton D, et al. . The PICHFORK (Pain in Children Fentanyl or Ketamine) trial: a randomized controlled trial comparing intranasal ketamine and fentanyl for the relief of moderate to severe pain in children with limb injuries. Ann Emerg Med 2015;65:e241:248–54.10.1016/j.annemergmed.2014.09.024
    1. Malinovsky JM, Servin F, Cozian A, et al. . Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. Br J Anaesth 1996;77:203–7.10.1093/bja/77.2.203
    1. Tsze DS, Steele DW, Machan JT, et al. . Intranasal ketamine for procedural sedation in pediatric laceration repair: a preliminary report. Pediatr Emerg Care 2012;28:767–70.10.1097/PEC.0b013e3182624935
    1. Yanagihara Y, Ohtani M, Kariya S, et al. . Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos 2003;24:37–43.10.1002/bdd.336
    1. Herd DW, Anderson BJ, Keene NA, et al. . Investigating the pharmacodynamics of ketamine in children. Paediatr Anaesth 2008;18:36–42.10.1111/j.1460-9592.2007.02384.x
    1. Wolfe TR, Braude DA. Intranasal medication delivery for children: a brief review and update. Pediatrics 2010;126:532–7.10.1542/peds.2010-0616
    1. Arya R, Gulati S, Kabra M, et al. . Intranasal versus intravenous lorazepam for control of acute seizures in children: a randomized open-label study. Epilepsia 2011;52:788–93.10.1111/j.1528-1167.2010.02949.x
    1. Borland M, Jacobs I, King B, et al. . A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department. Ann Emerg Med 2007;49:335–40.10.1016/j.annemergmed.2006.06.016
    1. Pires A, Fortuna A, Alves G, et al. . Intranasal drug delivery: how. why and what for? J Pharm Pharm Sci 2009;12:288–311.
    1. Chien YW, Kse S, Chang SF. Anatomy and physiology of the nose : Cheien YW, KSE S, Chang SF, Nasal systemic Drug delivery: drugs and the Pharmaceutical Sciences. New York: marcel Dekker Inc, 1989:1–19.
    1. Pandey RK, Bahetwar SK, Saksena AK, et al. . A comparative evaluation of drops versus atomized administration of intranasal ketamine for the procedural sedation of young uncooperative pediatric dental patients: a prospective crossover trial. J Clin Pediatr Dent 2011;36:79–84.10.17796/jcpd.36.1.1774746504g28656
    1. Jw V. PedsQL Sickle Cell Disease Module, Version 3.0. 1998.
    1. Palermo TM, Riley CA, Mitchell BA. Daily functioning and quality of life in children with sickle cell disease pain: relationship with family and neighborhood socioeconomic distress. J Pain 2008;9:833–40.10.1016/j.jpain.2008.04.002
    1. Varni J. Scaling and Scoring of the Pediatric Quality of Life Inventory (PedsQL) Condition-Specific modules (Version 12). Lyon, France: MAPI Research Trust 2013.
    1. Food and Drug Administration. Guidance for Clinical Trial Sponsors: Establishment andoperation of clinical trial data monitoring committees. 2006. OMB Control No:0910-0581 (accessed 1 Apr 2017).
    1. Harris PA, Taylor R, Thielke R, et al. . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81.10.1016/j.jbi.2008.08.010
    1. Sawe HR, Mfinanga JA, Lidenge SJ, et al. . Disease patterns and clinical outcomes of patients admitted in intensive care units of tertiary referral hospitals of Tanzania. BMC Int Health Hum Rights 2014;14:26.10.1186/1472-698X-14-26
    1. Sawe HR, Murray BL, Reynolds TA. Causes of fever in outpatient Tanzanian children. N Engl J Med 2014;370:2242.10.1056/NEJMc1403839#SA1
    1. Sawe HR, Mfinanga JA, Mwafongo V, et al. . Trends in mortality associated with opening of a full-capacity public emergency department at the main tertiary-level hospital in Tanzania. Int J Emerg Med 2015;8:24.10.1186/s12245-015-0073-4
    1. Sawe HR, Mfinanga JA, Ringo FH, et al. . Morbidity and mortality following traditional uvulectomy among children presenting to the Muhimbili National Hospital Emergency Department in Dar es Salaam, Tanzania. Emerg Med Int 2015;2015:1–5.10.1155/2015/108247
    1. Sawe HR, Mfinanga JA, Ringo FH, et al. . HIV counselling and testing practices for children seen in an urban emergency department of a tertiary referral hospital in Dar es Salaam, Tanzania: a retrospective cross-sectional study. BMJ Open 2016;6:e01029810.1136/bmjopen-2015-010298
    1. Hesseling PB, Njume E, Kouya F, et al. . The Cameroon 2008 Burkitt lymphoma protocol: improved event-free survival with treatment adapted to disease stage and the response to induction therapy. Pediatr Hematol Oncol 2012;29:119–29.10.3109/08880018.2011.644881
    1. Hesseling PB, Mbah G, Kouya F, et al. . Endemic Burkitt lymphoma: long-term outcome in 87 patients who presented with paraplegia in cameroon. Pediatr Hematol Oncol 2015;32:525–8.10.3109/08880018.2015.1085936
    1. Hesseling PB, Jam DT, Palmer DD, et al. . Burkitt's lymphoma patients in Northwest Cameroon have a lower incidence of sickle cell trait (Hb AS) than healthy controls. S Afr Med J 2016;106:686.10.7196/SAMJ.2016.v106i7.10693
    1. Paintsil V, David H, Kambugu J, et al. . The Collaborative wilms Tumour Africa Project; baseline evaluation of wilms tumour treatment and outcome in eight institutes in sub-Saharan Africa. Eur J Cancer 2015;51:84–91.10.1016/j.ejca.2014.10.030
    1. Morris L, Kouya F, Kwalar R, et al. . Factors associated with inconsistent condom use in adolescents with negative or unknown HIV status in Northwest Cameroon. AIDS Care 2014;26:1440–5.10.1080/09540121.2014.920948
    1. Pilapil M, Morris L, Saito K, et al. . Retrospective analysis of the prevalence of and factors associated with condom use among young HIV-infected women in Cameroon. SAGE Open Med 2016;4:205031211562643.10.1177/2050312115626432
    1. da Silva FC, Santos Thuler LC, de Leon-Casasola OA. Validity and reliability of two pain assessment tools in brazilian children and adolescents. J Clin Nurs 2011;20(13-14):1842–8.10.1111/j.1365-2702.2010.03662.x
    1. Hicks CL, von Baeyer CL, Spafford PA, et al. . The faces pain scale-revised: toward a common metric in pediatric pain measurement. Pain 2001;93:173–83.10.1016/S0304-3959(01)00314-1
    1. Huang KT, Owino C, Vreeman RC, et al. . Assessment of the face validity of two pain scales in Kenya: a validation study using cognitive interviewing. BMC Palliat Care 2012;11:5.10.1186/1472-684X-11-5
    1. Miró J, Huguet A. Evaluation of reliability, validity, and preference for a pediatric pain intensity scale: the Catalan version of the faces pain scale--revised. Pain 2004;111(1-2):59–64.10.1016/j.pain.2004.05.023
    1. Tomlinson D, von Baeyer CL, Stinson JN, et al. . A systematic review of faces scales for the self-report of pain intensity in children. Pediatrics 2010;126:e1168–e1198.10.1542/peds.2010-1609
    1. Tsze DS, von Baeyer CL, Bulloch B, et al. . Validation of self-report pain scales in children. Pediatrics 2013;132:e971–e979.10.1542/peds.2013-1509
    1. Panepinto JA, Torres S, Bendo CB, et al. . PedsQL™ sickle cell disease module: feasibility, reliability, and validity. Pediatr Blood Cancer 2013;60:1338–44.10.1002/pbc.24491

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit